Almirall’s open innovation platform AlmirallShare announces two new partnerships aimed at finding new ways for the treatment of skin cancer and atopic dermatitis

Almirall’s open innovation platform AlmirallShare announces two new partnerships aimed at finding new ways for the treatment of skin cancer and atopic dermatitis

• These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis
• AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 400 proposals since its launch in 2017

(PRESS RELEASE) BARCELONA, 24-Nov-2020 — /EuropaWire/ — Almirall, S.A. (BME: ALM), a Spanish pharmaceutical company, has announced that its open innovation platform AlmirallShare is bringing in two new collaborations with the University of South Australia and the Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau to find new pathways for the treatment of skin cancer and atopic dermatitis.

The collaboration with Prof. Tarl Prow, Research Professor at Future Industries Institute of the University of South Australia, is focused on generating knowledge about a common type of skin tumor. The aim is to elucidate the molecular mechanisms underlying squamous cell carcinoma and the modulation by a specific treatment. This group has a strong commitment to fight skin cancer and has developed innovative technologies with clinical applications and enhanced delivery of topical drugs. “We are excited to be joining forces with Almirall in this collaborative research project that allows us to establish synergies between different groups to follow our commitment to fight skin cancer. Pairing our deep knowledge of a common type of skin tumor with Almirall’s leading expertise in medical dermatology could reimagine the treatment options for people with skin carcinoma,” said Prof. Tarl Prow.

The project led by Prof. Dr. Lluís Puig, Director of Dermatology Department, and Prof. Silvia Vidal, Coordinator of Inflammatory Diseases Research Area, at Hospital de la Santa Creu i Sant Pau will focus on the understanding of biosignatures operating in atopic dermatitis in the different stages of the disease and in response to systemic therapy. The relationship between the skin immune cell composition, skin transcriptome and systemic biomarkers in atopic dermatitis patients will be investigated. “We strongly believe that this collaboration will boost new findings on atopic dermatitis, and it is a further step in future research on new treatments. We are very pleased to be joining forces with a leading medical dermatology company like Almirall.” stated Prof. Dr. Lluís Puig and Prof. Silvia Vidal.

AlmirallShare was launched in 2017 with the aim to facilitate collaborations in dermatological research and accelerate the generation of new treatments for skin conditions, by putting together the science and creativity of experts around the world with Almirall’s own expertise. Since then, more than 900 scientists have joined, and more than 400 proposals have been received. AlmirallShare is responsible for approximately 50% of the private-public collaborations driven by Almirall. These new collaborations are on top of the six collaborations that have already been established, based on new therapies (IDIBAPS, University of Turin), new targets (Dublin City University, University of Namur), and new preclinical models (University College Dublin, University of Sheffield).

“We are very pleased to start with these two new collaborations and establish close successful partnerships with them. We continue working to empower scientists to improve skin health and fostering collaboration projects with partners worldwide to make a real difference for patients living with skin conditions,” said Maribel Crespo, AlmirallShare leader.

New opportunities of collaboration

AlmirallShare reinforces its commitment to collaborative and shared innovation in R&D with a new call to establish collaborations in dermatological research, maximizing the preclinical assets’ value to find a breakthrough therapy for patients. The proposed asset should demonstrate a scientific rationale and therapeutic potential for treating dermatological conditions. In all cases, applicants will retain ownership of their intellectual property.

Scientists affiliated with start-ups, biotechs, universities, research centres, and pharmaceutical companies from anywhere in the world may submit their proposals on sharedinnovation.almirall.com. Assets submitted for consideration must be in late research or preclinical development stages, address a specific pathway, and demonstrate a therapeutic potential for treating dermatological conditions. Terms and conditions can be found on the website.

Scientists can also submit any proposal that may not fit with any of the open calls through the initiative Move your ideas forward.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need. The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

Almirall Media contact:

corporate.communication@almirall.com
T+ 34 932 913 000

SOURCE: Almirall, S.A.